Antibody-nanoparticle conjugates and methods for making and using such conjugates

Patent metadata

Field	Value
Publication number	US-11740233-B2
Application number	US-201816014965-A
Country	US
Kind code	B2
Filing date	Jun 21, 2018
Priority date	Apr 27, 2010
Publication date	Aug 29, 2023
Grant date	Aug 29, 2023

Abstract

Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.

First claim

We claim:

1. A method for producing an antibody-nanoparticle conjugate, comprising:
Providing a reduced intact antibody comprising 2 heavy chains and 2 light chains and having at least one thiol group, wherein the 2 heavy chains are covalently coupled to each other through at least one interchain disulfide bond; the reduced intact antibody is produced by reducing an intact antibody comprising two heavy chains and two light chains with dithiothreitol (DTT) under condition such that at least one thiol group is formed by reduction of at least one of a native interchain disulfide or a native intrachain disulfide of the intact antibody wherein the 2 heavy chains of the reduced intact antibody are covalently coupled to each other through at least one interchain disulfide bond; and
reacting the reduced intact antibody with an arylphosphine-nanoparticle composite and coupling the reduced intact antibody directly without an intervening linker to the arylphosphine-nanoparticle composite through the at least one formed thiol group through a metal-thiol bond, thereby producing the antibody-nanoparticle conjugate.

2. The method of claim 1 , further comprising adjusting reactant stoichiometry and reaction duration to couple two or more nanoparticles to the reduced antibody.

3. The method of claim 2 , wherein the antibody-nanoparticle conjugate comprises two to seven nanoparticles.

4. The method of claim 3 , wherein the antibody-nanoparticle conjugate comprises five nanoparticles.

5. The method of claim 2 , wherein the reactant stoichiometry of the arylphosphine-nanoparticle composite to the reduced antibody is about 7:1, and wherein the number of nanoparticles coupled to the reduced antibody is about five.

6. The method of claim 1 , wherein the nanoparticle is about 5 nm or less in diameter.

7. The method of claim 6 , wherein the nanoparticle is about 0.5 to about 5 nm in diameter.

8. The method of claim 1 , wherein the arylphosphine comprises 1 to 3 sulfonyl groups.

9. The method of claim 8 , wherein the arylphosphine is bis-(sulfonatophenyl)phenylphosphine.

10. The method of claim 1 , wherein the intact antibody comprises a rabbit, goat, mouse, or anti-hapten antibody.

11. The method of claim 10 , wherein the intact antibody is a rabbit anti-goat immunoglobulin G antibody.

12. The method of claim 1 , wherein the nanoparticle comprises gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof.

13. The method of claim 1 , wherein the arylphosphine-nanoparticle composite is an arylphosphine-gold nanoparticle composite.

14. The method of claim 13 , wherein the arylphosphine-gold nanoparticle composite is produced by a method comprising: reducing gold(III) to gold(I); reacting the gold(I) with sodium borohydride to produce gold nanoparticles; and reacting the gold nanoparticles with bis-(sulfonatophenyl)phenylphosphine.

15. The method of claim 14 , wherein reducing gold(III) to gold(I) comprises reacting auric acid with triphenylphosphine.

16. The method of claim 1 , wherein the antibody-nanoparticle conjugate is an antibody-gold nanoparticle conjugate, and wherein the reduced intact antibody is a reduced rabbit anti-goat immunoglobulin G (IgG) antibody; and the reacting step includes reacting the reduced intact rabbit anti-goat IgG antibody with a bis-(sulfonatophenyl)phenylphosphine (BSPP)-gold nanoparticle composite at a ratio of about 1:7, wherein the BSPP-gold nanoparticle composite is produced by reacting auric acid with triphenylphosphine, thereby producing an auric acid-triphenylphosphine mixture; reacting the auric acid-triphenylphosphine mixture with sodium borohydride to produce gold nanoparticles; and reacting the gold nanoparticles with BSPP, thereby producing the BSPP-gold nanoparticle composite, wherein about five gold nanoparticles are directly conjugated to the reduced intact rabbit anti-goat IgG antibody, thereby producing the antibody-gold nanoparticle conjugate.

17. The method of claim 1 , wherein each heavy chain of the intact reduced antibody is coupled to a light chain through an interchain disulfide bond.

18. The method of claim 1 , wherein the step of reducing involves reacting the intact antibody with the dithiothreitol for about 25 minutes.

19. The method of claim 1 , wherein the step of reducing involves reacting the intact antibody with the dithiothreitol at a temperature of about 4° C.

Assignees

• Ventana Med Syst Inc

Inventors

• Ashworth-Sharpe Julia
• Bieniarz Christopher
• Farrell Michael
• Johnson Donald D
• Kosmeder Jerome W
• Murillo Adrian E
• Yun Chol Steven
• Zhilina Zhanna

Classifications

• G01N33/54346 Primary

  Nanoparticles · CPC title

• C07F9/12

  with hydroxyaryl compounds · CPC title

• C07F9/5004

  Acyclic saturated phosphines · CPC title

• C07F9/5022

  Aromatic phosphines (P-C aromatic linkage) · CPC title

• C07F9/5045

  Complexes or chelates of phosphines with metallic compounds or metals · CPC title